Year: 2016
Type: article
Study design: Observational Study
Abstract: renal cell carcinoma (RCC) patients and to evaluate their validity regarding their diagnostic and outcome potential.METHODS: The study cohort included 40 healthy controls and 229 RCC patients (145 without metastases before nephrectomy, 84 with metastases before/during targeted therapy).cfDNA was isolated (1 ml EDTA plasma;QIAamp Circulating Nucleic Acid Kit) and qPCR analyses of genomic cfDNA of various gene fragments of amyloid beta (A4) precursor protein (67, 180, 306 bp) and ALU sequences (248/79 bp) and of mitochondrial cfDNA fragments (175/65 bp) were performed.RESULTS: The concentrations of the single cfDNA markers partially differed between the study groups while the five integrity indices (long to short fragments) differed between controls and metastatic patients, and two APP indices also to non-metastatic patients.Optimized combinations of different genomic and mitochondrial fragments (binary logistic regression) with two or three assays resulted in areas under the ROC curve of ¼0.78.In multivariate Cox regression analyses, optimized models for recurrence-free and overall survival were established using the prognostic potential of the individual cfDNA variables combined with the clinicopathological variables.Harrell's C-indices showed distinctly improved prognostic capabilities of these models in comparison to models based only on clinicopathological variables (increase:from 0.725 to 0.827; 0.701 to 0.836).CONCLUSIONS: Combinations of genomic and mitochondrial cfDNA are promising tools for urologists in the management of ccRCC patients both in diagnosis and prognosis.
Source: The Journal of Urology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2316196197